Key Account Manager (KAM) - Germany

Corcept Therapeutics

1 day ago

2.7 on Glassdoor

Berlin, Germany

Onsite

Full Time

Senior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

A Key Account Manager (KAM) – Oncology at Corcept supports the launch and growth of the company's oncology portfolio in Germany. The role focuses on driving awareness, adoption, and appropriate use of Corcept’s oncology products within key accounts across Germany through strategic account management, stakeholder engagement, and compliant promotional activities.

Skills

Qualifications

Bachelor’s degree in Life Sciences, Business, or a related fieldCertification as a Pharmaceutical Sales Representative (Pharmareferent/in) in accordance with §75 of the German Medicines Act (Arzneimittelgesetz, AMG)Recognized degree in pharmacy, medicine, chemistry, biology, or a related life-science disciplineSuccessful completion of the IHK Pharmareferent (IHK) certification or an equivalent recognized qualificationDemonstrated knowledge of German pharmaceutical law (AMG)

About Corcept Therapeutics

corcept.com

Corcept Therapeutics is a biopharmaceutical company that discovers and develops medicines that modulate the glucocorticoid receptor to treat disorders driven by excess cortisol. The company commercialized Korlym (mifepristone) for hyperglycemia secondary to endogenous Cushing’s syndrome and is advancing next‑generation, selective GR modulators (for example, relacorilant) through clinical development. Corcept combines translational science, clinical trials, and commercial capabilities to target endocrine and oncology indications where cortisol signaling contributes to disease. The company is headquartered in Menlo Park, California.

Recent company news

GlobeNewswire

CORCEPT THERAPEUTICS INCORPORATED (CORT) SHAREHOLDER ALERT

8 hours ago

Business Wire

REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026

1 day ago

TipRanks

Corcept Therapeutics Lawsuit: CORT Investors Face Losses After FDA Rejection and Alleged Misleading Statements

7 hours ago

Financial Times

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm – Company Announcement - FT.com

12 hours ago

ChartMill

Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT

19 hours ago